NClip

Decongestants

3 min read

Decongestants

Key Points

  • Phenylephrine and pseudoephedrine are alpha-1 agonists used for symptomatic nasal-congestion relief.
  • Alpha-1 stimulation causes vasoconstriction in nasal mucosa, reducing edema and improving airway patency.
  • Avoid use with MAOIs because severe interaction risk exists with sympathomimetic agents.
  • Do not use without a prescriber order in children younger than 4 years.
  • Use cautiously in glaucoma, hypertension, and benign prostatic enlargement.
  • Monitor for elevated blood pressure, urinary retention, nervousness, and insomnia.
  • Overuse of nasal-spray formulations can cause rebound congestion.

Mechanism of Action

Alpha-1 agonist decongestants constrict blood vessels in swollen nasal mucous membranes. This decreases local edema and secretions, opening upper-airway passages.

Indications

  • Short-term symptomatic relief of nasal congestion from common cold, hay fever, and other upper-respiratory allergy contexts.
  • Temporary relief of sinus congestion and pressure.

Nursing Considerations

  • Verify MAOI exposure before administration; concurrent use is contraindicated.
  • Decongestants are contraindicated in severe hypertension, coronary artery disease, narrow-angle glaucoma, and MAOI-associated antidepressant contexts.
  • Use caution in clients with cardiac dysrhythmias, hyperthyroidism, diabetes, or enlarged prostate.
  • Monitor for elevated blood pressure, urinary retention, restlessness, and sleep disturbance.
  • Avoid administration close to bedtime (source guidance: avoid within about 2 hours of sleep).
  • Reinforce legal purchase controls and quantity limits for pseudoephedrine products where applicable.

Adverse Effects

  • Headache
  • Hypertension and dysrhythmia
  • Dizziness, headache, excitability, restlessness, nervousness, or insomnia
  • Blurred vision, tinnitus, chest tightness, dry nose, and worsening nasal congestion in some clients
  • Rebound congestion with repeated topical nasal-spray use

Health Teaching

  • Take only as directed; do not double doses.
  • Do not exceed recommended dosing; overdose can cause severe nervousness, breathing difficulty, heart-rate changes, or hallucinations.
  • Report breathing difficulty, significant heart-rate change, severe agitation, or urinary retention promptly.
  • Limit topical decongestant-spray duration to reduce rebound congestion risk, and avoid prolonged spray/drop use beyond short-course guidance.
  • Maintain hydration as appropriate (commonly about 2-3 liters/day unless fluid restriction applies).

Clinical Judgment Application

Clinical Scenario

A patient with hypertension and BPH requests an OTC decongestant for severe nasal congestion.

  • Recognize Cues: Existing cardiovascular and urinary-risk conditions plus request for sympathomimetic medication.
  • Analyze Cues: Alpha-1 agonists can increase blood pressure and worsen urinary retention.
  • Prioritize Hypotheses: Priority is avoiding medication harm while addressing congestion symptoms.
  • Generate Solutions: Screen for MAOI use, recommend safer options (for example saline support), and escalate to prescriber/pharmacist when risk is high.
  • Take Action: Provide dosing-duration teaching and adverse-effect return precautions if use is approved.
  • Evaluate Outcomes: Congestion improves without blood-pressure rise, urinary retention, or rebound symptoms.

Graph View

Backlinks